Sunshine Biopharma vs Scilex Holding
Sunshine Biopharma is the larger business, with $36.3m of revenue in fiscal 2025 against $30.3m for Scilex Holding (1.2 times as much). Sunshine Biopharma grew faster (4.1% against -46.5%). Sunshine Biopharma kept more of each dollar of sales as profit: a net margin of -16.5% against -1236.4%.
| Latest fiscal year | Sunshine BiopharmaSBFM, 2025 | Scilex HoldingSCLX, 2025 |
|---|---|---|
| Revenue | $36.3m | $30.3m |
| Revenue growth | 4.1% | -46.5% |
| Net income | −$6.0m | −$374m |
| Operating margin | -17.2% | -1143.7% |
| Net margin | -16.5% | -1236.4% |
| Return on equity | -25.7% | — |
| Free cash flow | −$5.5m | $3.7m |
| Cash | $9.1m | $5.0m |
| Total debt | $0 | $106m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $0 | — |
| Employees | 50 | 34 |
| Market value | $6.5m | $13.4m |
| Price vs our value range | — | — |
| Moat score | 15 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 13 sales |